Back to News
Market Impact: 0.15
eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure
Source: Business Wire
Healthcare & BiotechCompany Fundamentals
eGenesis announced a clinical update from its ongoing expanded access study of EGEN-2784 in patients with kidney failure. The release is informational (no quantified efficacy/safety results provided in the excerpt), so near-term investor impact is likely limited pending the specific readouts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction
- A 44-minute call and a memo: How Alexandr Wang won Mark Zuckerberg’s trust—and a $100 billion-plus AI bet
- TSMC posts a sixth straight record profit but turns cautious on 2027
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search